Effect of desloratadine therapy on symptom scores and measures of nasal patency in seasonal allergic rhinitis: results of a single-center, placebo-controlled trial

This publication has 17 references indexed in Scilit:

• Comparison of the effects of desloratadine 5‐mg daily and placebo on nasal airflow and seasonal allergic rhinitis symptoms induced by grass pollen exposure
  Allergy, 2003
• Efficacy and safety of desloratadine 5 mg once daily in the treatment of chronic idiopathic urticaria: A double-blind, randomized, placebo-controlled trial*
  Journal of the American Academy of Dermatology, 2003
• Efficacy and safety of desloratadine in the treatment of perennial allergic rhinitis
  Journal of Allergy and Clinical Immunology, 2003
• Safety and efficacy of desloratadine 5 mg in asthma patients with seasonal allergic rhinitis and nasal congestion
  Annals of Allergy, Asthma & Immunology, 2002
• 24-hour efficacy of once-daily desloratadine therapy in patients with seasonal allergic rhinitis [ISRCTN32042139]
  BMC Family Practice, 2002
• Biochemical characterization of desloratadine, a potent antagonist of the human histamine H1 receptor
  European Journal of Pharmacology, 2002
• Effect of desloratadine versus placebo on nasal airflow and subjective measures of nasal obstruction in subjects with grass pollen–induced allergic rhinitis in an allergen-exposure unit
  Journal of Allergy and Clinical Immunology, 2002
• Allergic Rhinitis and Its Impact on Asthma
  Journal of Allergy and Clinical Immunology, 2001
• Efficacy and Tolerability of Once-Daily 5mg Desloratadine, an H1-Receptor Antagonist, in Patients with Seasonal Allergic Rhinitis
  Clinical Drug Investigation, 2001
• MANAGEMENT OF ALLERGIC RHINITIS
  Immunology and Allergy Clinics of North America, 2000